Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference

Core Insights - Anavex Life Sciences Corp. announced new data showing that blarcamesine significantly improves motor function and promotes dopaminergic nerve fiber regrowth in a new Parkinson's disease model [1][2][3] - The study presented at the AD/PD™ 2026 Conference indicates that blarcamesine can counteract and potentially reverse Parkinson's disease progression by addressing both alpha-synuclein accumulation and noradrenergic degeneration [2][3] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease and Parkinson's disease [1][6] - The lead drug candidate, ANAVEX2-73 (blarcamesine), has shown promise in multiple clinical trials, including Phase 2a and Phase 2b/3 for Alzheimer's disease and a Phase 2 proof-of-concept study for Parkinson's disease dementia [6][7] - The company has received research funding from the Michael J. Fox Foundation to support the development of ANAVEX2-73 for Parkinson's disease [7]